Population-based analysis of treatment patterns and outcomes for pancreas cancer in Victoria.
hepatopancreaticobiliary surgery
pancreas
surgical oncology
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
01
08
2019
revised:
03
11
2019
accepted:
07
12
2019
pubmed:
30
4
2020
medline:
15
5
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
The Victorian Pancreas Cancer summit 2017 analysed state-wide data on management of Victorians with pancreas cancer between 2011 and 2015 to identify variations in care and outcomes. Pancreas cancer remains a formidable disease but systemic therapies are increasingly effective. Surgery remains essential but insufficient alone for cure. Understanding patterns of care and identifying variations in treatment is critical to improving outcomes. This population-based study analysed data collected prospectively by Department of Health and Human services (Victorian state government). Data were extracted from Victorian Cancer Registry (covering all Victorian cancer diagnoses), Victorian Admitted-Episodes Dataset (all inpatient data), Victorian Radiotherapy Minimum Dataset and Victorian Death Index providing demographics, tumour and treatment characteristics, age-standardized incidence, overall and median survival. Of 3962 Victorian patients with any form of pancreatic malignancy, 82% were ductal adenocarcinoma (PDAC), of whom 67% had metastases at diagnosis. One-year overall survival for PDAC was 30% (60% non-metastatic, 15% if metastatic). Median survival with metastases increased from 2.7 to 3.9 months, and from 13.3 to 15.9 months for non-metastatic PDAC between 2011 and 2015. Thirty-one percent of non-metastatic patients underwent pancreatectomy. About 1.5% were treated with neoadjuvant chemotherapy/chemoradiation. Of patients undergoing intended curative resection, 77% proceeded to adjuvant therapy. Fifty-one percent of metastatic PDAC patients never received anti-tumour therapy. Nearly one-fourth of surgically treated patients never received systemic therapy. More than two-thirds of non-metastatic patients never proceeded to surgery. Further consideration of neoadjuvant therapy should be given to borderline resectable patients. Most patients with PDAC still die soon after diagnosis, but median survival is increasing.
Sections du résumé
BACKGROUND
The Victorian Pancreas Cancer summit 2017 analysed state-wide data on management of Victorians with pancreas cancer between 2011 and 2015 to identify variations in care and outcomes. Pancreas cancer remains a formidable disease but systemic therapies are increasingly effective. Surgery remains essential but insufficient alone for cure. Understanding patterns of care and identifying variations in treatment is critical to improving outcomes.
METHODS
This population-based study analysed data collected prospectively by Department of Health and Human services (Victorian state government). Data were extracted from Victorian Cancer Registry (covering all Victorian cancer diagnoses), Victorian Admitted-Episodes Dataset (all inpatient data), Victorian Radiotherapy Minimum Dataset and Victorian Death Index providing demographics, tumour and treatment characteristics, age-standardized incidence, overall and median survival.
RESULTS
Of 3962 Victorian patients with any form of pancreatic malignancy, 82% were ductal adenocarcinoma (PDAC), of whom 67% had metastases at diagnosis. One-year overall survival for PDAC was 30% (60% non-metastatic, 15% if metastatic). Median survival with metastases increased from 2.7 to 3.9 months, and from 13.3 to 15.9 months for non-metastatic PDAC between 2011 and 2015. Thirty-one percent of non-metastatic patients underwent pancreatectomy. About 1.5% were treated with neoadjuvant chemotherapy/chemoradiation. Of patients undergoing intended curative resection, 77% proceeded to adjuvant therapy. Fifty-one percent of metastatic PDAC patients never received anti-tumour therapy.
CONCLUSIONS
Nearly one-fourth of surgically treated patients never received systemic therapy. More than two-thirds of non-metastatic patients never proceeded to surgery. Further consideration of neoadjuvant therapy should be given to borderline resectable patients. Most patients with PDAC still die soon after diagnosis, but median survival is increasing.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1677-1682Informations de copyright
© 2020 Royal Australasian College of Surgeons.
Références
Australian Institute of Health and Welfare. Australian Institute of Health and Welfare Annual Report. Canberra: Australian Govt. Pub. Service. 2017.
Quan H, Li B, Couris CM et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 2011; 173: 676-82.
Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-1957). Tohoku University School of Medicine: Department of Public Health, 1960.
Sohal DP, Walsh RM et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J. Natl. Cancer Inst. 2014; 106: dju011.
Hishinuma S, Ogata Y et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J. Gastrointest. Surg. 2006; 10: 511-8.
Burmeister EA, O'Connell DL et al. Describing patterns of care in pancreatic cancer: a population-based study. Pancreas 2015; 44: 1259-65.
Katz MH, Pisters PW et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J. Am. Coll. Surg. 2008; 206: 833-46 discussion 846-838.
Callery MP, Chang KJ et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann. Surg. Oncol. 2009; 16: 1727-33.
Bockhorn M, Uzunoglu FG et al. Borderline resectable pancreatic cancer: a consensus statement by the international study Group of Pancreatic Surgery (ISGPS). Surgery 2014; 155: 977-88.
Gandy RC, Barbour AP et al. Refining the care of patients with pancreatic cancer: the AGITG pancreatic cancer workshop consensus. Med. J. Aust. 2016; 204: 419-22.
Isaji S, Mizuno S et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18: 2-11.
Burmeister EA, O'Connell DL et al. Factors associated with quality of care for patients with pancreatic cancer in Australia. Med. J. Aust. 2016; 205: 459-65.
Bilimoria KY, Bentrem DJ et al. National failure to operate on early stage pancreatic cancer. Ann. Surg. 2007; 246: 173-80.
Shaib WL, Ip A, Cardona K et al. Contemporary management of borderline resectable and locally advanced unresectable pancreatic cancer. Oncologist 2016; 21: 178-87.
Tempero MA, Malafa MP et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 2014; 12: 1083-93.
Schorn S, Demir IE et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - a systematic review and meta-analysis. Cancer Treat. Rev. 2017; 55: 96-106.
Chandrasegaram MD, Goldstein D et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br. J. Surg. 2015; 102: 1459-72.
Strobel O, Hank T et al. Pancreatic cancer surgery: the new R-status counts. Ann. Surg. 2017; 265: 565-73.
Rankin NM, Lai M et al. Cancer multidisciplinary team meetings in practice: results from a multi-institutional quantitative survey and implications for policy change. Asia Pac. J. Clin. Oncol. 2018; 14: 74-83.
Lamb BW, Brown KF et al. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann. Surg. Oncol. 2011; 18: 2116-25.
Swanson RS, Pezzi CM et al. The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the national cancer data base. Ann. Surg. Oncol. 2014; 21: 4059-67.
Speer AG, Thursfield VJ et al. Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. Med. J. Aust. 2012; 196: 511-5.
LGM V-G et al. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer Med. 2017; 6: 2840-9.
Beesley VL, Janda M et al. A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. Psychooncology 2016; 25: 150-7.
Agarwal R, Epstein AS. Palliative care and advance care planning for pancreas and other cancers. Chin. Clin. Oncol. 2017; 6: 32.
Sohal DPS, Kennedy EB et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 2018; 36: 2545-56.
Fogel EL, Shahda S et al. A multidisciplinary approach to pancreas cancer in 2016: a review. Am. J. Gastroenterol. 2017; 112: 537-54.
Eagar K, Watters P et al. The Australian palliative care outcomes collaboration (PCOC) - measuring the quality and outcomes of palliative care on a routine basis. Aust. Health Rev. 2010; 34: 186-92.